
## **Gernot Zollner**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6280004/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Recent advances on FXR-targeting therapeutics. Molecular and Cellular Endocrinology, 2022, 552, 111678.	1.6	27
2	Clinical-Pathological Conference Series from the Medical University of Graz. Wiener Klinische Wochenschrift, 2021, 133, 731-740.	1.0	1
3	Hypercortisolism in patients with cholestasis is associated with disease severity. BMC Gastroenterology, 2021, 21, 460.	0.8	3
4	Changes in the Intestinal Microbiome during a Multispecies Probiotic Intervention in Compensated Cirrhosis. Nutrients, 2020, 12, 1874.	1.7	25
5	Bile acids increase steroidogenesis in cholemic mice and induce cortisol secretion in adrenocortical H295R cells via S1 <scp>PR</scp> 2, <scp>ERK</scp> and <scp>SF</scp> â€1. Liver International, 2019, 39, 2112-2123.	1.9	12
6	Bile acids and glucocorticoid metabolism in health and disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 243-251.	1.8	18
7	To salt or not to salt?—That is the question in cirrhosis. Liver International, 2018, 38, 1148-1159.	1.9	27
8	Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis. Journal of Hepatology, 2018, 69, 368-377.	1.8	27
9	Genetic loss of the muscarinic M <sub>3</sub> receptor markedly alters bile formation and cholestatic liver injury in mice. Hepatology Research, 2018, 48, E68-E77.	1.8	10
10	Ultrasound verified inflammation and structural damage in patients with hereditary haemochromatosis-related arthropathy. Arthritis Research and Therapy, 2017, 19, 243.	1.6	13
11	Secretin and cholestasis, two sides of a coin. Hepatology, 2016, 64, 714-716.	3.6	0
12	Clinical–Pathological Conference Series from the Medical University of Graz. Wiener Klinische Wochenschrift, 2016, 128, 277-286.	1.0	1
13	The chronic kidney disease epidemiology collaboration equation combining creatinine and cystatin C accurately assesses renal function in patients with cirrhosis. BMC Nephrology, 2015, 16, 196.	0.8	30
14	Alterations of Canalicular ATP-Binding Cassette Transporter Expression in Drug-Induced Liver Injury. Digestion, 2014, 90, 81-88.	1.2	19
15	Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. , 2010, 126, 228-243.		79
16	Nuclear receptors as therapeutic targets in cholestatic liver diseases. British Journal of Pharmacology, 2009, 156, 7-27.	2.7	143
17	Mechanisms of Cholestasis. Clinics in Liver Disease, 2008, 12, 1-26.	1.0	166
18	Hepatobiliary Transporter Expression in Intercellular Adhesion Molecule 1 Knockout and Fas Receptor-Deficient Mice after Common Bile Duct Ligation Is Independent of the Degree of Inflammation and Oxidative Stress. Drug Metabolism and Disposition, 2007, 35, 1694-1699.	1.7	12

GERNOT ZOLLNER

#	Article	IF	Citations
19	Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver International, 2007, 27, 920-929.	1.9	103
20	Role of Nuclear Receptors in the Adaptive Response to Bile Acids and Cholestasis:Â Pathogenetic and Therapeutic Considerations. Molecular Pharmaceutics, 2006, 3, 231-251.	2.3	288
21	Molecular mechanisms of cholestasis. Wiener Medizinische Wochenschrift, 2006, 156, 380-385.	0.5	57
22	Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-1±/1² in the adaptive response to bile acids. American Journal of Physiology - Renal Physiology, 2006, 290, G923-G932.	1.6	154
23	Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. American Journal of Physiology - Renal Physiology, 2005, 289, G798-G805.	1.6	67
24	Ursodeoxycholic acid aggravates bile infarcts in bile duct–ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology, 2002, 123, 1238-1251.	0.6	287
25	Beyond PXR and CAR, Regulation of Xenobiotic Metabolism by other Nuclear Receptors. , 0, , 275-300.		Ο